Overview

Evaluation of JSKN016 Combination Therapy in Subjects with NSCLC

Status:
NOT_YET_RECRUITING
Trial end date:
2028-12-30
Target enrollment:
Participant gender:
Summary
This is a Phase Ib clinical study conducted in China to evaluate the treatment of advanced non-small cell lung cancer with JSKN016 in combination therapy. The enrolled subjects are all in the locally advanced or metastatic stage of non-small cell lung cancer.
Phase:
PHASE1
Details
Lead Sponsor:
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Treatments:
aflutinib
Carboplatin
Docetaxel
pembrolizumab
tislelizumab